Shares of Biogen, a US biotech company, trade around 50% higher in premarket today. Shares rally following results of an Alzheimer drug (Lecanemab) trial that Biogen developed along with Eisai, Japanese pharmaceutical company. Results showed that the pace of cognitive decline in patients who received Lecanemab dropped by 27% over 18 months compared to patients who received placebo. This is massive as it is the first drug to show effectiveness against Alzheimer in a definitive, large-scale trial. While the company noted that some side effects occurred, it also said that they were rarely severe.
Biogen trades around 50% higher in premarket today. Weekly chart. Source: xStation5
Defence sector earnings: Saab, Safran, Lockheed Martin
ServiceNow plunges 13% after earnings 📉Software sell-off kick-off again?
Stock of the Week - Schneider Electric: The Quiet Foundation of the AI and Global Electrification Revolution
Nvidia dominates Big Tech again 🗽 What does the U.S. earnings season show?